Researchers commonly utilise MT-2 in broader in-vitro studies involving receptor-related signalling models and peptide stability investigations
Its systemic effects make it useful for broader recovery support rather than isolated treatment areas alone
Eli Lilly published the results of its ATTAIN-1b trial for obesity in September 2025 7 , which compared orforglipron to placebo in more than 3,100 adults without diabetes, with a BMI of 30+ or 27-30 with an obesity-related complication including hypertension, dyslipidaemia, cardiovascular disease or obstructive sleep apnoea and a history of at least one patient-reported unsuccessful dietary effort to lose body weight, who have tried unsuccessfully to lose weight with diet alone
Their antioxidant properties help combat free radicals caused by UV exposure, enhancing the effectiveness of broad-spectrum sunscreens
Lu YY, Li H, Ren H, Zhang X, Huang F, Zhang D, Huang Q, Zhang X